Our Work

The Consortium’s work represents the largest and most comprehensive assessment of the effects of SGLT2 inhibitors and has been featured in leading general medical and specialty journals.

SGLT2 inhibitors and risk of hyperkalemia in people with type 2 diabetes

Impact of diabetes on the effects of SGLT2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

Sodium glucose co-transporter 2 inhibitors and major adverse cardiovascular outcomes: A SMART-C Collaborative Meta-Analysis